Fast Market Research

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies - New Market Report

Recently published research from GBI Research, "Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies", is now available at Fast Market Research

 

Boston, MA -- (SBWIRE) -- 11/25/2014 -- GBI Research, the leading business intelligence provider, has released its latest research, "Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies", which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Colorectal Cancer (CRC). The market in the APAC region was worth an estimated $1.9 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% to $1.9 billion in 2020. The use of targeted therapies is expected to increase in the Asia-Pacific (APAC) markets (for the purposes of this report, APAC refers to Australia, China, India and Japan only), as patient access to these more expensive agents improves. The moderate uptake of late-stage pipeline products panitumumab and Xilonix, following their expected approval, is expected to drive additional growth within this market. Others such as ramucirumab, TAS-102, TS-1, MelCancerVac will also contribute. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC CRC market.

View Full Report Details and Table of Contents

Scope

The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the four APAC markets of Australia, China, India and Japan. It includes -

- A brief introduction to CRC, including the disease's pathogenesis, etiology, diagnosis and treatment algorithms

- In-depth analysis of currently marketed drugs for CRC, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy

- A comprehensive review of the pipeline for CRC, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target

- Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type

- Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets

- Discussion of the drivers of and barriers to market growth

- In-depth analysis of all licensing and co-development deals that have occurred in the CRC market since 2006

Reasons to Get This Report

The report will enhance your decision-making capability by allowing you to -

- Understand the CRC pipeline and the factors that indicate that it is becoming more innovative

- Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be

- Follow the trends in CRC clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates

- Observe the potential growth patterns expected for the CRC market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the CRC market

- Accelerate and strengthen your market position by identifying key companies for strategic partnerships

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 800-844-8156

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies
- Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth
- Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market
- Acute Myeloid Leukemia Therapeutics Market to 2020 - Novel Therapies to Offer Clinical Benefit in Small Patient Cohorts
- Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options
- Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019
- Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth
- Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth
- PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
- Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth